natgillin/translations-raw huggingface dataset:
Levetiracetam Hospira is an anti-epileptic medicine that contains the active substance levetiracetam. 
Levetiracetam Hospira je zdravilo proti epilepsiji, ki vsebuje zdravilno učinkovino levetiracetam.
When Levetiracetam Hospira is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day. 
Kadar se zdravilo Levetiracetam Hospira uporablja samostojno, je začetni odmerek 250 mg dvakrat na dan, ki se dva tedna pozneje poveča na 500 mg dvakrat na dan. Odmerek se lahko glede na bolnikov odziv še naprej povečuje v dvotedenskih presledkih do največjega odmerka 1 500 mg dvakrat na dan.
How has Levetiracetam Hospira been studied? 
Kako je bilo zdravilo Levetiracetam Hospira raziskano?
How is Levetiracetam Hospira used? 
Kako se zdravilo Levetiracetam Hospira uporablja?
No additional studies were needed as Levetiracetam Hospira is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Keppra. 
Ker je zdravilo Levetiracetam Hospira generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Keppra, niso bile potrebne nobene dodatne študije.
How does Levetiracetam Hospira work? 
Kako zdravilo Levetiracetam Hospira deluje?
The medicine is used in: 
Zdravilo se uporablja pri:
Further information on Myalepta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Myalepta so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
However, the medicine does not restore fat tissue under the skin. 
Vendar zdravilo ne obnavlja maščobnega tkiva v pod kožo.
It also results in insulin resistance (when the body is unable to recognise insulin, a hormone that helps regulate blood sugar levels). 
Prav tako povzroča odpornost na insulin (ko telo ne more prepoznati insulina, hormona, ki pomaga uravnavati ravni sladkorja v krvi).
Patients or carers can inject the medicine themselves once they have been trained. 
Bolniki ali njihovi skrbniki lahko po ustreznem usposabljanju zdravilo injicirajo sami.
What measures are being taken to ensure the safe and effective use of Myalepta? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Myalepta?
The European Medicines Agency therefore decided that Myalepta's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Myalepta večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Myalepta has been shown to be effective at lowering blood fat levels in 2 main studies involving a total of 107 adults and children with generalised or partial lipodystrophy. 
Zdravilo Myalepta se je izkazalo za učinkovito pri zmanjševanju ravni maščob v krvi v dveh glavnih študijah, v kateri je bilo vključenih skupaj 107 odraslih in otrok z generalizirano ali parcialno lipodistrofijo.
Myalepta has been authorised under ‘exceptional circumstances'. 
Zdravilo Myalepta je pridobilo dovoljenje za promet „v izjemnih okoliščinah“.
The recommended daily dose depends on the patient's bodyweight and is adjusted based on the patient's response to treatment. 
Priporočeni dnevni odmerek je odvisen od telesne mase bolnika in se prilagaja glede na njegov odziv na zdravljenje.
After 12 months of treatment, blood levels of fats (triglycerides) decreased from around 15 mmol/l to around 5 mmol/l in patients with generalised disease, and from around 16 mmol/l to around 6 mmol/l in patients with partial disease. 
Po 12 mesecih zdravljenja se je raven maščob v krvi (trigliceridov) znižala s približno 15 mmol/l na približno 5 mmol/l pri bolnikih z generalizirano boleznijo in s približno 16 mmol/l na približno 6 mmol/l pri bolnikih s parcialno boleznijo.
In the studies Myalepta was not compared with any other treatment. 
V študijah zdravila Myalepta niso primerjali z nobenim drugim zdravilom.
Insulin resistance was also improved: blood levels of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, fell from 8.6% to 6.4% in patients with generalised lipodystrophy, and from 8.8% to 8.0% in patients with partial lipodystrophy. 
Izboljšala se je tudi odpornost na insulin: ravni glikoziliranega hemoglobina (HbA1c) v krvi, ki kaže, kako dobro se nadzira glukoza v krvi, so se znižale z 8,6 % na 6,4 % pri bolnikih z generalizirano lipodistrofijo in z 8,8 % na 8,0 % pri bolnikih s parcialno lipodistrofijo.
As for all medicines, data on the use of Myalepta are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Myalepta stalno spremljajo.
Patients with lipodystrophy have low levels of a human hormone called leptin, which plays a key role in regulating the break-down of fats and sugars in the body. 
Bolniki z lipodistrofijo imajo nizke ravni človeškega hormona, imenovanega leptin, ki ima ključno vlogo pri uravnavanju razgradnje maščob in sladkorjev v telesu.
Because the number of patients with the various forms of lipodystrophy is low, the diseases are considered ‘rare', and Myalepta was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 July 2012. 
Ker je bolnikov z različnimi oblikami lipodistrofije malo, veljajo bolezni za „redke“, zato je bilo zdravilo Myalepta 17. julija 2012 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
This leads to loss of fat from under the skin and its build-up in places such as the liver and muscles, as well as high levels of fat in the blood. 
To povzroča izgubo maščobe pod kožo in njeno kopičenje na mestih, kot so jetra in mišice, ter visoko raven maščob v krvi.
The most common side effects with Myalepta (which may affect more than 1 in 10 people) are hypoglycaemia (low blood glucose) and weight loss. 
Najpogostejša neželena učinka zdravila Myalepta (ki se lahko pojavita pri več kot 1 od 10 bolnikov) sta hipoglikemija (nizka raven glukoze v krvi) in izguba telesne mase.
It replaces leptin and increases fat breakdown in the blood, muscles and liver, thereby correcting some abnormalities in patients with lipodystrophy, including insulin resistance. 
Ta nadomešča leptin in povečuje razgradnjo maščob v krvi, mišicah in jetrih, s tem pa odpravlja nekatere nepravilnosti pri bolnikih z lipodistrofijo, vključno z odpornostjo na insulin.
Why is Myalepta authorised in the EU? 
Zakaj je bilo zdravilo Myalepta odobreno v EU?
Side effects reported with Myalepta are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Myalepta, se skrbno ovrednotijo in po potrebi sprejmejo ukrepi za zaščito bolnikov.
Other information about Myalepta 
Druge informacije o zdravilu Myalepta
An overview of Myalepta and why it is authorised in the EU 
Pregled zdravila Myalepta in zakaj je odobreno v EU
Myalepta has been shown to correct some abnormalities caused by leptin deficiency in patients with lipodystrophy, a rare condition for which few treatments are available. 
Pokazalo se je, da zdravilo Myalepta odpravlja nekatere nepravilnosti, ki jih povzroča pomanjkanje leptina pri bolnikih z lipodistrofijo, redko boleznijo, za katero je na voljo malo možnosti zdravljenja.
Myalepta is given as a daily injection under the skin of the abdomen (belly), thigh or upper arm, at the same time every day. 
Zdravilo Myalepta je v obliki injekcije, ki se enkrat na dan daje pod kožo abdomna (trebuha), stegna ali nadlahti, vsak dan ob enakem času.
What benefits of Myalepta have been shown in studies? 
Kakšne koristi zdravila Myalepta so se pokazale v študijah?
What are the risks associated with Myalepta? 
Kakšna tveganja so povezana z zdravilom Myalepta?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Myalepta have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Myalepta upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What is Myalepta and what is it used for? 
Kaj je zdravilo Myalepta in za kaj se uporablja?
For more information about using Myalepta, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Myalepta glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The active substance in Myalepta, metreleptin, is similar to leptin. 
Učinkovina v zdravilu Myalepta, metreleptin, je podobna leptinu.
Since Myalepta has been authorised under exceptional circumstances, the company that markets Myalepta will set-up a registry of patients treated the medicine, and conduct studies to further investigate the benefits and risks of treatment including the possibility for Myalepta to trigger the production of antibodies. 
Ker je zdravilo Myalepta pridobilo dovoljenje za promet v izjemnih okoliščinah, bo podjetje, ki ga trži, zagotovilo seznam bolnikov, ki prejemajo zdravilo, in izvedlo študije za nadaljnjo raziskavo koristi in tveganj zdravljenja, vključno z možnostjo, da zdravilo Myalepta sproži tvorbo protiteles.
The company that markets Myalepta will provide educational materials to patients and doctors with detailed information on how to use the medicine and what to do in case of side effects, including allergic reactions, hypoglycaemia and serious infections. 
Podjetje, ki trži zdravilo Myalepta, bo bolnikom in zdravnikom zagotovilo izobraževalno gradivo s podrobnimi informacijami o uporabi zdravila in ukrepanju v primeru neželenih učinkov, vključno z alergijskimi reakcijami, hipoglikemijo in resnimi okužbami.
Side effects seen with Myalepta are of the kind expected from this type of treatment. 
Neželeni učinki zdravila Myalepta so pričakovani za to vrsto zdravljenja.
• adults and children above the age of 12 years with partial (localised) lipodystrophy (including Barraquer-Simons syndrome), when standard treatments have failed. 
• odraslih in otrocih, starejših od 12 let, s parcialno (lokalizirano) lipodistrofijo (vključno z Barraquer
Myalepta is a medicine used in addition to diet to treat lipodystrophy, where patients have loss of fatty tissue under the skin and build-up of fat elsewhere in the body such as in the liver and muscles. 
Zdravilo Myalepta je zdravilo, ki se uporablja kot dodatek prehrani za zdravljenje lipodistrofije, pri kateri imajo bolniki premalo maščobnega tkiva pod kožo in kopičijo maščobo drugje v telesu, na primer v jetrih in mišicah.
What information is still awaited for Myalepta? 
Katere informacije o zdravilu Myalepta še pričakujemo?
Myalepta can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the diagnosis and management of patients with metabolic disorders. 
Predpisovanje in izdaja zdravila Myalepta je le na recept, zdravljenje z njim pa mora uvesti in spremljati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolnikov s presnovnimi motnjami.
For the full list of side effects and restrictions with Myalepta, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Myalepta glejte navodilo za uporabo.
Myalepta contains the active substance metreleptin. 
Zdravilo Myalepta vsebuje učinkovino metreleptin.
This is because it has not been possible to obtain complete information about Myalepta due to the rarity of the condition. 
To pomeni, da zaradi redkosti bolezni ni bilo mogoče pridobiti vseh podatkov o zdravilu.
• adults and children above the age of 2 years with generalised (throughout the body) lipodystrophy (Berardinelli-Seip syndrome and Lawrence syndrome); 
• odraslih in otrocih, starejših od dveh let, z generalizirano (po celotnem telesu) lipodistrofijo
How is Myalepta used? 
Kako se zdravilo Myalepta uporablja?
How does Myalepta work? 
Kako zdravilo Myalepta deluje?
It must also not be used in patients who are suspected to have had in the past an allergic reaction called ‘allergic contact dermatitis' to Exelon patch. 
Prav tako ga ne smejo uporabljati bolniki, pri katerih obstaja sum, da so v preteklosti doživeli alergijsko reakcijo, imenovano „alergijski kontaktni dermatitis“, na obliže zdravila Exelon.
The full EPAR for Rivastigmine 1 A Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Rivastigmine 1 A Pharma je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Rivastigmine 1 A Pharma should be given twice a day, with morning and evening meals. 
Zdravilo Rivastigmine 1 A Pharma se daje dvakrat na dan ob jutranjem in večernem obroku.
The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine 1 A Pharma on 11 December 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Rivastigmine 1 A Pharma, veljavno po vsej Evropski uniji, odobrila 11. decembra 2009.
This is a summary of the European public assessment report (EPAR) for Rivastigmine 1 A Pharma. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rivastigmine 1 A Pharma.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Rivastigmine 1 A Pharma by the patient. 
Zdravljenje se lahko začne samo, če je na voljo negovalec, ki bo pri bolniku redno spremljal uporabo zdravila Rivastigmine 1 A Pharma.
Overall, the most common side effects include nausea (feeling sick, seen in 38 patients in 100) and vomiting (seen in 23 patients in 100), particularly during the phase when the dose of Rivastigmine 1 A Pharma is being increased. 
Na splošno sta med najpogostejšimi neželenimi učinki navzeja (slabost, opažena pri 38 bolnikih od 100) in bruhanje (opaženo pri 23 bolnikih od 100), zlasti v obdobju povečevanja odmerka zdravila Rivastigmine 1 A Pharma.
For more information about treatment with Rivastigmine 1 A Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rivastigmine 1 A Pharma preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP concluded that Rivastigmine 1 A Pharma has a modest effectiveness in treating the symptoms of Alzheimer's dementia, although this does reflect an important benefit in some patients. 
CHMP je zaključil, da ima zdravilo Rivastigmine 1 A Pharma pri zdravljenju simptomov Alzheimerjeve demence skromen učinek, čeprav ta pomeni pomembno korist za nekatere bolnike.
Rivastigmine 1 A Pharma must not be used in people who are hypersensitive (allergic) to rivastigmine, other carbamate derivatives or any of the other ingredients. 
Zdravila Rivastigmine 1 A Pharma ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) rivastigmin, druge derivate karbamata ali katero koli drugo sestavino zdravila.
Rivastigmine 1 A Pharma was more effective than placebo at controlling symptoms. 
Zdravilo Rivastigmine 1 A Pharma je bilo pri obvladovanju simptomov učinkovitejše od placeba.
Treatment with Rivastigmine 1 A Pharma should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease. 
Zdravljenje z zdravilom Rivastigmine 1 A Pharma mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
The Committee initially concluded that for the treatment of dementia due to Parkinson's disease, Rivastigmine 1 A Pharma's benefits did not outweigh its risks. 
Odbor je prvotno sklenil, da za zdravljenje demence, ki je posledica Parkinsonove bolezni, koristi zdravila Rivastigmine 1 A Pharma ne odtehtajo njegovih tveganj.
Therefore, the Committee decided that Rivastigmine 1 A Pharma's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je zato menil, da so koristi zdravila Rivastigmine 1 A Pharma večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
All of the studies lasted six months and compared the effects of Rivastigmine 1 A Pharma with those of placebo (a dummy treatment). 
Vse študije so trajale šest mesecev, v njih pa so učinke zdravila Rivastigmine 1 A Pharma primerjali z učinki placeba (zdravila brez zdravilne učinkovine).
Rivastigmine 1 A Pharma is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 
Zdravilo Rivastigmine 1 A Pharma se uporablja za zdravljenje bolnikov z blago do zmerno hudo Alzheimerjevo demenco, tj. napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
An additional study in 27 patients was used to show that Rivastigmine 1 A Pharma capsules and oral solution produced similar levels of the active substance in the blood. 
Z dodatno študijo s 27 bolniki so dokazali, da kapsule in peroralna raztopina zdravila Rivastigmine 1 A Pharma dosegajo podobne ravni zdravilne učinkovine v krvi.
Rivastigmine 1 A Pharma has been studied in three main studies involving 2,126 patients with mild to moderately severe Alzheimer's disease. 
Zdravilo Rivastigmine 1 A Pharma so proučevali v treh glavnih študijah, v katerih je sodelovalo 2 126 bolnikov z blago do zmerno hudo obliko Alzheimerjeve bolezni.
Rivastigmine 1 A Pharma was also studied in 541 patients with dementia due to Parkinson's disease. 
Zdravilo Rivastigmine 1 A Pharma so proučevali tudi pri 541 bolnikih z demenco kot posledico Parkinsonove bolezni.
The global symptom score also improved more in the patients taking Rivastigmine 1 A Pharma. 
Tudi rezultat celostne ocene simptomov je bil boljši pri bolnikih, ki so jemali zdravilo Rivastigmine 1 A Pharma.
Other information about Rivastigmine 1 A Pharma 
Druge informacije o zdravilu Rivastigmine 1 A Pharma
In the three studies of Rivastigmine 1 A Pharma in patients with Alzheimer's dementia, patients taking doses of Rivastigmine 1 A Pharma between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance. 
V treh študijah zdravila Rivastigmine 1 A Pharma pri bolnikih z Alzheimerjevo demenco je bilo pri tistih, ki so jemali od 6- do 9-miligramske odmerke zdravila Rivastigmine 1 A Pharma, opaziti povprečno povečanje kognitivnih simptomov za 0,2 točke od izhodiščne vrednosti 22,9 točke na začetku študije, pri čemer nižji rezultat pomeni boljšo učinkovitost.
By blocking these enzymes, Rivastigmine 1 A Pharma allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease. 
Zdravilo Rivastigmine 1 A Pharma z zaviranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rivastigmine 1 A Pharma. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Rivastigmine 1 A Pharma, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Rivastigmine 1 A Pharma is a medicine containing the active substance rivastigmine. 
Rivastigmine 1 A Pharma je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
The patients with dementia due to Parkinson's disease taking Rivastigmine 1 A Pharma capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points. 
Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Rivastigmine 1 A Pharma, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
For the global score, patients taking Rivastigmine 1 A Pharma had an increase in symptoms of 4.1 points, compared with 4.4 in those taking placebo. 
Kar zadeva rezultat celostne ocene simptomov, je pri bolnikih, ki so jemali zdravilo Rivastigmine 1 A Pharma, prišlo do povečanja simptomov za 4,1 točke v primerjavi s 4,4 točke pri tistih, ki so jemali placebo.
For the full list of all side effects reported with Rivastigmine 1 A Pharma, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rivastigmine 1 A Pharma, glejte navodilo za uporabo.
What benefit has Rivastigmine 1 A Pharma shown during the studies? 
Kakšne koristi je zdravilo Rivastigmine 1 A Pharma izkazalo med študijami?
The types of side effects seen with Rivastigmine 1 A Pharma depend on the type of dementia it is being used to treat. 
Vrste neželenih učinkov, opaženih pri zdravilu Rivastigmine 1 A Pharma, so odvisne od vrste demence, ki se zdravi.
Rivastigmine 1 A Pharma is also used to treat mild to moderately severe dementia in patients with Parkinson's disease. 
Zdravilo se lahko uporablja tudi za zdravljenje blage do zmerno hude demence pri bolnikih s Parkinsonovo boleznijo.
The active substance in Rivastigmine 1 A Pharma, rivastigmine, is an antidementia medicine. 
Zdravilna učinkovina zdravila Rivastigmine 1 A Pharma, rivastigmin, je zdravilo za zdravljenje demence.
What is the risk associated with Rivastigmine 1 A Pharma? 
Kakšna tveganja so povezana z zdravilom Rivastigmine 1 A Pharma?
Why has Rivastigmine 1 A Pharma been approved? 
Zakaj je bilo zdravilo Rivastigmine 1 A Pharma odobreno?
What is Rivastigmine 1 A Pharma? 
Kaj je zdravilo Rivastigmine 1 A Pharma?
How has Rivastigmine 1 A Pharma been studied? 
Kako je bilo zdravilo Rivastigmine 1 A Pharma raziskano?
What is Rivastigmine 1 A Pharma used for? 
Za kaj se zdravilo Rivastigmine 1 A Pharma uporablja?
How is Rivastigmine 1 A Pharma used? 
Kako se zdravilo Rivastigmine 1 A Pharma uporablja?
How does Rivastigmine 1 A Pharma work? 
Kako zdravilo Rivastigmine 1 A Pharma deluje?
Some of the areas harmonised include: 
Nekatera področja, ki jih je treba uskladiti, so:
It must also not be used in the second and third trimesters (the last six months) of pregnancy. 
Prav tako se ne sme uporabljati v drugem in tretjem trimesečju (zadnjih šest mesecev) nosečnosti.
János Borvendég (Hungary) 
János Borvendég (Madžarska)
The company that markets these medicines is F. Hoffmann - La Roche Ltd. 
Družba, ki trži ta zdravila, je F. Hoffmann - La Roche Ltd.
Vascace should be taken once a day at about the same time each day. 
Zdravilo Vascace je treba vzeti enkrat na dan, vsak dan ob približno istem času.
The usual dose is 2.5 to 5 mg per day. 
Običajen odmerek je 2,5 do 5 mg na dan.
Treatment with diuretics (medicines that help increase the amount of water removed from the body in the urine) should, where possible, be stopped two to three days before starting treatment with Vascace. 
Zdravljenje z diuretiki (zdravila, ki pomagajo povečati količino vode, izločene iz telesa z urinom) je treba, kadar je to mogoče, dva do tri dni pred pričetkom zdravljenja z zdravilom Vascace, prekiniti.
Vascace is authorised in the EU via national procedures. 
Zdravilo Vascace je v EU odobreno z nacionalnimi postopki.
Vascace is also available in the EU under other trade names: Dynorm, Inhibace, Inibace, Justor and Vascase. 
Zdravilo Vascace je v EU na voljo tudi pod drugimi trgovskimi imeni: Dynorm, Inhibace, Inibace, Justor in Vascase.
Patients with impairment of kidney function may have to take lower doses. 
Bolniki z okvarjenim delovanjem ledvic bodo morali morda jemati manjše odmerke.